NO861461L - Fosfinforbindelser. - Google Patents
Fosfinforbindelser.Info
- Publication number
- NO861461L NO861461L NO861461A NO861461A NO861461L NO 861461 L NO861461 L NO 861461L NO 861461 A NO861461 A NO 861461A NO 861461 A NO861461 A NO 861461A NO 861461 L NO861461 L NO 861461L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- pyridyl
- compounds
- bis
- compound
- Prior art date
Links
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 title description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 239000003960 organic solvent Substances 0.000 claims description 24
- 239000000460 chlorine Substances 0.000 claims description 22
- -1 chlorosulfuric acid tetrahydrate Chemical compound 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 19
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 14
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000007858 starting material Substances 0.000 claims description 11
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 claims description 9
- 229950006389 thiodiglycol Drugs 0.000 claims description 9
- PMCMJPXEJUKOAO-UHFFFAOYSA-M gold(1+);bromide Chemical compound [Au]Br PMCMJPXEJUKOAO-UHFFFAOYSA-M 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 235000009518 sodium iodide Nutrition 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 125000001979 organolithium group Chemical group 0.000 claims description 3
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract description 33
- 229910052737 gold Inorganic materials 0.000 abstract description 33
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 230000004565 tumor cell growth Effects 0.000 abstract description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 3
- 125000004437 phosphorous atom Chemical group 0.000 abstract description 2
- 229910052717 sulfur Inorganic materials 0.000 abstract description 2
- 125000004434 sulfur atom Chemical group 0.000 abstract description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000010931 gold Substances 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 12
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- NGDNCZPCIZNCQS-UHFFFAOYSA-N ctk3j8699 Chemical compound Cl=S NGDNCZPCIZNCQS-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- GBLNXAZZONXIQE-UHFFFAOYSA-N 2-dipyridin-2-ylphosphanylethyl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)CCP(C=1N=CC=CC=1)C1=CC=CC=N1 GBLNXAZZONXIQE-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000001273 butane Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 6
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 6
- 239000008389 polyethoxylated castor oil Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000001294 propane Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- SBWAJHLQMFBNIN-UHFFFAOYSA-N dichloro(2-dichlorophosphanylethyl)phosphane Chemical compound ClP(Cl)CCP(Cl)Cl SBWAJHLQMFBNIN-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 4
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 4
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000191368 Chlorobi Species 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KHMYIIPFUJCUEK-UHFFFAOYSA-N 1-diethylphosphanylethyl(diethyl)phosphane Chemical compound CCP(CC)C(C)P(CC)CC KHMYIIPFUJCUEK-UHFFFAOYSA-N 0.000 description 2
- MIOCUERTSIJEDP-UHFFFAOYSA-N 2-diethylphosphanylethyl(diethyl)phosphane Chemical compound CCP(CC)CCP(CC)CC MIOCUERTSIJEDP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- VZZJVOCVAZHETD-UHFFFAOYSA-N diethylphosphane Chemical compound CCPCC VZZJVOCVAZHETD-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002343 gold Chemical class 0.000 description 2
- ATGIETUGWDAYPU-UHFFFAOYSA-M gold monoiodide Chemical compound [Au]I ATGIETUGWDAYPU-UHFFFAOYSA-M 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ILJKKPLHRPIQLD-UHFFFAOYSA-N sulfurochloridic acid;hydrate Chemical compound O.OS(Cl)(=O)=O ILJKKPLHRPIQLD-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- KDKMTIRSYIHSTB-MROZADKFSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=S KDKMTIRSYIHSTB-MROZADKFSA-N 0.000 description 1
- ZDXOURSGHNOFHL-VFQQELCFSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ZDXOURSGHNOFHL-VFQQELCFSA-N 0.000 description 1
- ABXYOVCSAGTJAC-DPYQTVNSSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-DPYQTVNSSA-N 0.000 description 1
- WWPRMQSMBRFAPZ-KCDKBNATSA-N (2s,3r,4r,5s)-2,3,4,5-tetrahydroxyhexanethial Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=S WWPRMQSMBRFAPZ-KCDKBNATSA-N 0.000 description 1
- ABXYOVCSAGTJAC-KVTDHHQDSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=S ABXYOVCSAGTJAC-KVTDHHQDSA-N 0.000 description 1
- FAHAFPWNBVQHLR-UHFFFAOYSA-N 1-[bis(furan-2-yl)phosphanyl]butan-2-yl-bis(furan-2-yl)phosphane Chemical compound C=1C=COC=1P(C=1OC=CC=1)C(CC)CP(C=1OC=CC=1)C1=CC=CO1 FAHAFPWNBVQHLR-UHFFFAOYSA-N 0.000 description 1
- DXHVPISORHAEMD-UHFFFAOYSA-N 1-[bis(furan-2-yl)phosphanyl]hexan-2-yl-bis(furan-2-yl)phosphane Chemical compound C=1C=COC=1P(C=1OC=CC=1)C(CCCC)CP(C=1OC=CC=1)C1=CC=CO1 DXHVPISORHAEMD-UHFFFAOYSA-N 0.000 description 1
- JETSBSXZJNEONQ-UHFFFAOYSA-N 1-[bis(furan-2-yl)phosphanyl]pentan-2-yl-bis(furan-2-yl)phosphane Chemical compound C=1C=COC=1P(C=1OC=CC=1)C(CCC)CP(C=1OC=CC=1)C1=CC=CO1 JETSBSXZJNEONQ-UHFFFAOYSA-N 0.000 description 1
- PKDVEWYYZQMQAZ-UHFFFAOYSA-N 1-[bis(furan-2-yl)phosphanyl]propan-2-yl-bis(furan-2-yl)phosphane Chemical compound C=1C=COC=1P(C=1OC=CC=1)C(C)CP(C=1OC=CC=1)C1=CC=CO1 PKDVEWYYZQMQAZ-UHFFFAOYSA-N 0.000 description 1
- WGOBPPNNYVSJTE-UHFFFAOYSA-N 1-diphenylphosphanylpropan-2-yl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)CP(C=1C=CC=CC=1)C1=CC=CC=C1 WGOBPPNNYVSJTE-UHFFFAOYSA-N 0.000 description 1
- AIFHNSYXLIQRPY-UHFFFAOYSA-N 1-dipyridin-2-ylphosphanylbutan-2-yl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)C(CC)CP(C=1N=CC=CC=1)C1=CC=CC=N1 AIFHNSYXLIQRPY-UHFFFAOYSA-N 0.000 description 1
- MNBISBPVXBVMHY-UHFFFAOYSA-N 1-dipyridin-2-ylphosphanylhexan-2-yl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)C(CCCC)CP(C=1N=CC=CC=1)C1=CC=CC=N1 MNBISBPVXBVMHY-UHFFFAOYSA-N 0.000 description 1
- PVRIDWJPKKASSA-UHFFFAOYSA-N 1-dipyridin-2-ylphosphanylpentan-2-yl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)C(CCC)CP(C=1N=CC=CC=1)C1=CC=CC=N1 PVRIDWJPKKASSA-UHFFFAOYSA-N 0.000 description 1
- VWJZXCXPLIOBJA-UHFFFAOYSA-N 1-dipyridin-2-ylphosphanylpropan-2-yl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)C(C)CP(C=1N=CC=CC=1)C1=CC=CC=N1 VWJZXCXPLIOBJA-UHFFFAOYSA-N 0.000 description 1
- KUAVHCBLXVYTAB-UHFFFAOYSA-N 1-dipyridin-4-ylphosphanylbutan-2-yl(dipyridin-4-yl)phosphane Chemical compound C=1C=NC=CC=1P(C=1C=CN=CC=1)C(CC)CP(C=1C=CN=CC=1)C1=CC=NC=C1 KUAVHCBLXVYTAB-UHFFFAOYSA-N 0.000 description 1
- BGFJZPMGISHGJP-UHFFFAOYSA-N 1-dipyridin-4-ylphosphanylhexan-2-yl(dipyridin-4-yl)phosphane Chemical compound C=1C=NC=CC=1P(C=1C=CN=CC=1)C(CCCC)CP(C=1C=CN=CC=1)C1=CC=NC=C1 BGFJZPMGISHGJP-UHFFFAOYSA-N 0.000 description 1
- UVQKEUCUSPPQFB-UHFFFAOYSA-N 1-dipyridin-4-ylphosphanylpentan-2-yl(dipyridin-4-yl)phosphane Chemical compound C=1C=NC=CC=1P(C=1C=CN=CC=1)C(CCC)CP(C=1C=CN=CC=1)C1=CC=NC=C1 UVQKEUCUSPPQFB-UHFFFAOYSA-N 0.000 description 1
- WLOIESKQSGIRMR-UHFFFAOYSA-N 1-dithiophen-2-ylphosphanylhexan-2-yl(dithiophen-2-yl)phosphane Chemical compound C=1C=CSC=1P(C=1SC=CC=1)C(CCCC)CP(C=1SC=CC=1)C1=CC=CS1 WLOIESKQSGIRMR-UHFFFAOYSA-N 0.000 description 1
- HQIFCQINNOMTII-UHFFFAOYSA-N 1-dithiophen-2-ylphosphanylpentan-2-yl(dithiophen-2-yl)phosphane Chemical compound C=1C=CSC=1P(C=1SC=CC=1)C(CCC)CP(C=1SC=CC=1)C1=CC=CS1 HQIFCQINNOMTII-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OHXAKBURQXRNQJ-UHFFFAOYSA-N 2-dipyridin-4-ylphosphanylethyl(dipyridin-4-yl)phosphane Chemical compound C=1C=NC=CC=1P(C=1C=CN=CC=1)CCP(C=1C=CN=CC=1)C1=CC=NC=C1 OHXAKBURQXRNQJ-UHFFFAOYSA-N 0.000 description 1
- XOBXDKKTLAHVKM-UHFFFAOYSA-N 2-dithiophen-2-ylphosphanylethyl(dithiophen-2-yl)phosphane Chemical compound C=1C=CSC=1P(C=1SC=CC=1)CCP(C=1SC=CC=1)C1=CC=CS1 XOBXDKKTLAHVKM-UHFFFAOYSA-N 0.000 description 1
- KAVIXEFDMXCWGJ-UHFFFAOYSA-N 3-dipyridin-2-ylphosphanylpropyl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)CCCP(C=1N=CC=CC=1)C1=CC=CC=N1 KAVIXEFDMXCWGJ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229910003771 Gold(I) chloride Inorganic materials 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- JYULNMQVMVQBEZ-OUAUKWLOSA-N [(2r,3r,4r)-3,4-diacetyloxy-1-hydroxy-5-sulfanylidenepentan-2-yl] acetate Chemical compound CC(=O)O[C@H](CO)[C@@H](OC(C)=O)[C@@H](OC(C)=O)C=S JYULNMQVMVQBEZ-OUAUKWLOSA-N 0.000 description 1
- FPEMWQZJYZMECA-KNFQTBNASA-N [(2s,3r,4r,5s)-3,4-diacetyloxy-5-hydroxy-1-sulfanylidenehexan-2-yl] acetate Chemical compound CC(=O)O[C@H]([C@@H](O)C)[C@@H](OC(C)=O)[C@H](OC(C)=O)C=S FPEMWQZJYZMECA-KNFQTBNASA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5045—Complexes or chelates of phosphines with metallic compounds or metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO874954A NO874954D0 (no) | 1985-04-16 | 1987-11-27 | Fosfinforbindelser. |
| NO882368A NO882368D0 (no) | 1985-04-16 | 1988-05-30 | Fosfinforbindelser. |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72377885A | 1985-04-16 | 1985-04-16 | |
| US73452485A | 1985-05-16 | 1985-05-16 | |
| US73601885A | 1985-05-20 | 1985-05-20 | |
| US82935986A | 1986-02-14 | 1986-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO861461L true NO861461L (no) | 1986-10-17 |
Family
ID=27505566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861461A NO861461L (no) | 1985-04-16 | 1986-04-15 | Fosfinforbindelser. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0198696B1 (da) |
| DE (1) | DE3670291D1 (da) |
| DK (1) | DK166686A (da) |
| ES (2) | ES8801295A1 (da) |
| FI (1) | FI861557A (da) |
| NO (1) | NO861461L (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8704181A1 (es) * | 1985-01-22 | 1987-03-16 | Smithkline Beckman Corp | Un procedimiento para preparar un compuesto de bis (difenilfosfino) alquil -bis-oro-i |
| US4880902A (en) * | 1987-08-27 | 1989-11-14 | Shell Oil Company | Copolymerization of carbon monoxide and olefin with diphosphine having heterocyclic substituents as catalyst |
| US5274125A (en) * | 1991-03-15 | 1993-12-28 | Hoffmann-La Roche Inc. | Chirale phosphines |
| AU686918B2 (en) * | 1994-12-09 | 1998-02-12 | Griffith University | Anti-tumour agents |
| MX2016009397A (es) * | 2015-07-23 | 2017-03-30 | Evonik Degussa Gmbh | Compuestos basados en ferroceno y catalizadores de paladio basados en los mismos para la alcoxicarbonilacion de compuestos etilenicamente insaturados. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1238854A (en) * | 1984-02-01 | 1988-07-05 | David T. Hill | ANTITUMOR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUMORS EMPLOYING ¬.alpha.,W- BIS(DISUBSTITUTEDPHOSPHINO)HYDROCARBON| DIGOLD (I) DIGOLD (III), DISILVER (I) AND DICOPPER (I) DERIVATIVES |
| PH21350A (en) * | 1984-06-04 | 1987-10-13 | Smithkline Beckman Corp | Tumor cell growth imhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes |
-
1986
- 1986-04-11 DK DK166686A patent/DK166686A/da active IP Right Grant
- 1986-04-14 DE DE8686302749T patent/DE3670291D1/de not_active Expired - Fee Related
- 1986-04-14 EP EP86302749A patent/EP0198696B1/en not_active Expired - Lifetime
- 1986-04-14 FI FI861557A patent/FI861557A/fi not_active Application Discontinuation
- 1986-04-15 ES ES553979A patent/ES8801295A1/es not_active Expired
- 1986-04-15 NO NO861461A patent/NO861461L/no unknown
-
1987
- 1987-08-17 ES ES557678A patent/ES8801296A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI861557A0 (fi) | 1986-04-14 |
| ES553979A0 (es) | 1987-12-16 |
| EP0198696B1 (en) | 1990-04-11 |
| FI861557A (fi) | 1986-10-17 |
| DK166686A (da) | 1986-10-17 |
| ES8801296A1 (es) | 1987-12-16 |
| ES557678A0 (es) | 1987-12-16 |
| DE3670291D1 (en) | 1990-05-17 |
| EP0198696A3 (en) | 1988-01-07 |
| ES8801295A1 (es) | 1987-12-16 |
| DK166686D0 (da) | 1986-04-11 |
| EP0198696A2 (en) | 1986-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petragnani | Aryl tellurium trihalides—I | |
| Talancon et al. | Diastereomerically pure platinum (II) complexes as antitumoral agents.: The influence of the mode of binding {(N),(N, O)− or (C, N)}− of (1S, 2R)[(η5-C5H5) Fe {(η5-C5H4) CHNCH (Me) CH (OH) C6H5}] and the arrangement of the auxiliary ligands | |
| Weber et al. | Advances and recent trends in dipnictenes chemistry | |
| CA1238854A (en) | ANTITUMOR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUMORS EMPLOYING ¬.alpha.,W- BIS(DISUBSTITUTEDPHOSPHINO)HYDROCARBON| DIGOLD (I) DIGOLD (III), DISILVER (I) AND DICOPPER (I) DERIVATIVES | |
| Meyer et al. | Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands | |
| EP0164970B1 (en) | Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes | |
| Safa et al. | Organoplatinum complexes with an ester substituted bipyridine ligand: Oxidative addition and supramolecular chemistry | |
| NO861461L (no) | Fosfinforbindelser. | |
| Miller | A Pyrolytic Synthesis of Ylides. Isolation of Trimethylphosphinetrimethylsilylmethylene | |
| Canty et al. | Interaction of palladium (II) acetate with substituted pyridines, including a cyclometallation reaction and the structure of [Pd {meso-[(py) PhMeC] 2 C 5 H 3 N}(O 2 CMe)][O 2 CMe]· 3H 2 O | |
| Ghavale et al. | Synthesis, structure and reactivity of a selenoxide derived from a bulky selenide: Bis (2, 4, 6-trimethylphenyl) selenoxide | |
| NO882368L (no) | Fosfinforbindelser. | |
| NO874954L (no) | Fosfinforbindelser. | |
| US3718679A (en) | Phosphine or phosphite gold complexes of thiomalic acid | |
| US4902675A (en) | "2-pyridyl and 4-pyridyl phosphine gold (I) anti tumor complexes" | |
| Chopade et al. | Synthesis and characterization of (ethylenediamine)/(diammine) platinum (II) coordinated to seleno ligands containing carboxylic acid functionality | |
| Pannell | Organometalloidal derivatives of the transition metals: V. A 1, 2-alkyl shift from lead to a transition metal | |
| Barone et al. | A NMR, X-ray, and DFT combined study on the regio-chemistry of nucleophilic addition to platinum (II) coordinated terminal olefins | |
| US4716230A (en) | Certain bis(di-2 or 4-pyridyl-phosphino) alkanes #10 having anti-tumor properties | |
| Weir et al. | Stereochemistry and metal-centered rearrangements of eight-coordinate niobium (V) and tantalum (V) dithiocarbamates and monothiocarbamates | |
| US4755611A (en) | Certain bio-(bi-2-thienyl or 2-furyl phosphino) lower alkanes having anti-tumor properties | |
| Annibale et al. | A 1H nuclear magnetic resonance study of the mechanism of the reaction between cis-dichlorobis (dimethyl sulfoxide)-platinum (II) and nitrogen donors | |
| US4764509A (en) | Pharmaceutical compositions containing di-gold phosphine | |
| US4698422A (en) | Triphos and tetraphos gold compounds and ligands | |
| Khanc et al. | Synthesis, Structural Investigations and Biological Screening of Diorganotin (IV) Complexes Derived from 5, 5-Diethyl Sodium Barbital |